Otsuka Holdings Co., Ltd.
4578.THealthcareTSEDrug Manufacturers - General · Last scanned Jun 3, 2026
Scan Results
Daily timeframeOtsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. Valued at $5.68T, 4578.T is a mega-cap name in its sector. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoimmune space digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices.
Market Cap
$5.68T
Beta
-0.05
P/E (TTM)
15.75
P/E (Fwd)
20.78
EPS (TTM)
$685.14
EPS (Fwd)
$519.18
ROE
12.9%
ROA
7.5%
Cash
$538.30B
Total Debt
$194.63B
Free CF
—
52W Change
62.8%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $538.30B in cash comfortably exceeding the $194.63B debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Return on equity stands at 12.9%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 7.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $1.74T (2022) to $2.47T (2025), reflecting a 42% increase over the period.
4578.T's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Otsuka Holdings Co., Ltd. and its sector.